Claims
- 1. A method of transforming hematopoietic cells which comprise T lymphocytes, said method comprising the steps of:(a) providing viral particles comprising a foreign nucleic acid sequence which comprises: (i) a regulatory nucleic acid sequence which is expressable in T lymphocytes and which can be activated by a signal supplied to said T lymphocytes by an antigen that induces graft versus host disease, and (ii) a nucleic acid sequence that encodes a product which, when contacted in situ with a pharmaceutical substance, reacts with said substance to induce destruction of said T lymphocytes, wherein said nucleic acid sequence is operably linked to said regulatory nucleic acid sequence; and (b) culturing said viral particles, under conditions suitable for cell culturing, with said T lymphocytes, thereby transforming said T lymphocytes with said foreign nucleic acid sequence.
- 2. The method of claim 1, wherein said regulatory sequence is an interleukin-2 promoter or an interleukin-2 receptor promoter.
- 3. The method of claim 1, wherein said viral particles are arnphotropic Moloney virus particles produced by a packaging cell line.
- 4. The method of claim 1, wherein said product, when reacted with said pharmaceutical substance, induces an interruption of DNA replication in said T lymphocytes.
- 5. The method of claim 4, wherein said product is thymidine kinase.
- 6. A method of transforming hematopoietic cells which comprise T lymphocytes, said method comprising the steps of:(a) providing viral particles comprising a foreign nucleic acid sequence which comprises: (i) a regulatory nucleic acid sequence which is expressable in T lymphocytes and which can be activated by a signal supplied to said T lymphocytes by an antigen that induces graft versus h6st disease, and (ii) a nucleic acid sequence that encodes thymidine kinase which is operably linked to said regulatory nucleic acid sequence; and (b) culturing said viral particles, under conditions suitable for cell culturing, with said T lymphocytes, thereby transforming said T lymphocytes with said foreign nucleic acid sequence.
- 7. A method of transforming hematopoietic cells which comprise T lymphocytes, said method comprising the steps of:(a) providing amphotropic retroviral particles comprising a foreign nucleic acid sequence which comprises: (i) a regulatory nucleic acid sequence which is capable of expression in T lymphocytes and which can be activated by a signal supplied to said T lymphocytes by an antigen that induces graft versus host disease, and (ii) a nucleic acid sequence that encodes a product which, when contacted in situ with a pharmaceutical substance, reacts with said substance to induce destruction of said T lymphocytes, wherein said nucleic acid sequence is operably linked to said regulatory nucleic acid sequence; and (b) culturing said amphotropic retroviral particles, under conditions suitable for cell culturing, with said T lymphocytes, thereby transforming said T lymphocytes with said foreign nucleic acid sequence.
- 8. A population of T lymphocytes comprising a foreign nucleic acid sequence, wherein said foreign nucleic acid sequence comprises a regulatory nucleic acid sequence which is expressed by an activation signal supplied to said T lymphocytes by an antigen that induces graft versus host disease, and a nucleic acid sequence that encodes a product which, when contacted in situ with a pharmaceutical substance, reacts with said substance to induce destruction of said T lymphocytes, wherein said nucleic acid sequence is operably linked to said regulatory nucleic acid sequence.
- 9. The population of T lymphocytes of laim 8, wherein said regulatory nucleic acid sequence is an interleukin-2 promoter or an interleukin-2 receptor promoter.
- 10. The population of T lymphocytes of claim 8, wherein said product, when reacted with said pharmaceutical substance, induces an interruption of DNA replication in said T lymphocytes.
- 11. The population of T lymphocytes of claim 10, wherein said product is thymidine kinase.
Priority Claims (1)
Number |
Date |
Country |
Kind |
91 13430 |
Oct 1991 |
FR |
|
RELATED APPLICATION
The present Application is a continuation-in-part of Application No. 08/482,799, filed Jun. 7, 1995, now U.S. Pat. No. 6,048,525, which is a continued prosecution application of U.S. Ser. No. 08/084,242, filed Nov. 9, 1993, which claims priority to French application No. PCT/FR92/0106, filed Oct. 30, 1992.
Non-Patent Literature Citations (1)
Entry |
L. K. Venkatesh et al. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 tat by a conditionally cytotoxic adenovirus vector. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/084242 |
Nov 1993 |
US |
Child |
08/482799 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/482799 |
Jun 1995 |
US |
Child |
09/442557 |
|
US |